India, Aug. 6 -- On August 5, 2026, the U.S. Food and Drug Administration (FDA) approved Moderna's mFlusiva (mRNA-1010), marking the first-ever messenger RNA-based vaccine cleared for seasonal influenza. The vaccine is authorized for adults aged 50 and older, targeting the upcoming 2026-2027 respiratory virus season.

FDA Approves Cambridge-based Moderna's mRNA Flu Vaccine

The U.S. Food and Drug Administration (FDA) has officially approved mFLUSIVA (mRNA-1010), Cambridge-based Moderna's seasonal influenza vaccine for adults 50 years of age and older, making it the world's first approved messenger RNA-based flu shot. This milestone marks a major shift in public health, proving that the mRNA platform can expand beyond COVID-19 and RSV into...